Private equity continues to snap up physician groups

Private equity firms are continuing their investments in physician practices, scooping up 355 acquisitions from 2013 to 2016, according to a new study published in JAMA.

The pace of acquisitions also increased over time, from 59 practices in 2013 to 136 in 2016, according to the findings. Other reports suggest that acquisitions in 2017 to 2018 also accelerated, though those dates weren’t included in the data set. The number of acquisitions meant private equity firms took over 1,426 sites of care and more than 5,700 physicians over the study period.

Researchers used data of physician group practices by private equity firms from the Irving Levin Associates Health Care M&A reports, excluding practices that were bought by non-private equity firms. They also Googled the specifics of the practices to verify them.

Private equity firms preferred to acquire practices with several sites of care and many physicians, expecting greater than 20% annual returns on their investments.

The findings come at a time when physician-owned practices are at an all-time low, and the effects of this change in ownership on patients and employees are unclear, particularly with firms looking to capitalize on the transactions. Practices may also face other revenue pressures under private equity ownership.

“These financial incentives may conflict with the need for longer-term investments in practice stability, physician recruitment, quality and safety,” wrote lead author Jane M. Zhu, MD, MPP, MSHP, of the division of general internal medicine and geriatrics at Oregon Health & Science University, et al.

 

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.